Modern approaches to treatment and recurrence prevention of papillomavirus-infection treatment at women of reproductive age


  • Е. Н. Борис NMAPE them. PLShupyk; Center for evidence-based medicine; GUZO Kyiv, Ukraine



papillomavirus infection, іndole-3-carbinol, epigallocatechin, Epigalin, epytelial dysplasia


Reproductive Technologies, Ukrainian State Institute of Reproduction, National Medical Academy of Postgraduate Education named after P.L. Shupyk

Some modern literature data and results of our own observations and research for effective methods of the complex treatment of papillomavirus-infection have been presented. The importance of Еpigalin in eliminating of viruses, facilitating of the clinical course (colposcopical status), prevention of relapses of papillomavirus disease is studied.

The study included 65 women of reproductive age infected with human papilloma virus (HPV) with the cervix dysplasia. Women were divided into two groups: observation group (35 women) and control group (30 patients). Patients of observation group were prescribed complex antiviral therapy duration of 6 months, which included Epigalin. Patients of the control group were prescribed etiotropic (antiviral) therapy without Epigalin.

The clinical effect at the end of treatment (HPV elimination) was achieved in 94% of patients of the observation group. The clinical effect in the control group was achieved in only 60% of women. These data allow us to recommend Epigalin in the treatment of precancerous cervical diseases on the HPV background.

Author Biography

Е. Н. Борис, NMAPE them. PLShupyk; Center for evidence-based medicine; GUZO Kyiv

PhD, Associate Professor, Department of Obstetrics, Gynecology and Reproduction;


chief reproductologist


  1. Adaskevich, V.P. Sexually transmitted infections infections. Nizhny Novgorod. Medical Book (2004): 424 p.
  2. Ayzyatulov, R.F. Sexually transmitted diseases. Donetsk. Donechchina (2000): 384 p.
  3. Kohanevich, E.V. Actual issues of obstetrics, gynecology and reproductive. M. Triada-X (2006): 480 p.
  4. Apolikhina, I.A. Genital HPV infection in women. M. Dynasty (2002): 54–62.
  5. Bashmakova, M.A., Savicheva, A.M. HPV infection. M. Med Book (2002): 32 p.
  6. Bebneva, T.N., Prylepskaia, V.N. “HPV infection and cervical pathology.” Gynecology, 3(3) (2001): 77–81.
  7. Bohman, Y.V. Oncogynecology Guidelines. SPb. Publisher Foliant Ltd (2002): 542 p.
  8. Bohman, Y.V., Rybin E.P. Polyneoplasia of the reproductive system. SPb. Neva-Lux (2001): 240 p.
  9. Vyshnevskaia, E.E. Precancerous diseases and malignant tumors of the female genital organs. Minsk. Vysheishaia School (2002): 416 p.
  10. Vorobyova, L.І., Ligirda, N.F. “The role of antiviral therapy in the treatment of mild cervical intraepithelial neoplasia.” Women’s Health, 7(43) (2009): 125–128.
  11. Gilyazutdinova, E.S., Mikhailova, M.K. Oncogynecology. M. MEDpress-Inform (2002): 283 p.
  12. Kartashov, S.M., Beloded, O.A. “Analysis of the effectiveness of immunomodulators in the treatment of human papillomavirus infection.” Women’s Health, 7(43) (2009): 161–164.
  13. Kiselev, V.I. “Human papillomaviruses in cervical cancer development.” M. Comp. Schedule Group (2004): 9–47.
  14. Center for Disease Control and Prevention of the United States (CDC) clinical guideline on the management of patients infected with human papillomavirus, 2006. Health of Ukraine (2007): 56–57.
  15. Kohanevych, E.V., Ganina, K.P., Sumenko, V.V. Colpocervicoscopy. Atlas. K. High school (2004): 56 p.
  16. Kohanevych, E.V., et al. Cervix and uterus pathology. Manual for Physicians. Nizhin. Gydromaks (2009): 148–153.
  17. Kustarov, V.N., Linde, V.A. Cervical Pathology. SPb. Hippocrates (2002): 144 p.
  18. Minkina, G.N., Manukhin, I.B., Frank, G.A. Precancer of the cervix. M. Aerografmedia (2001): 117 p.
  19. Prylepskaia, V.N. Diseases of the cervix, vagina and vulva. M. MEDpress-Inform (2005): 430 p.
  20. Prylepskaia, V.N., Rogovskaia, S.I., Kondrikov, N.I., Suhyh, G.T. Human papillomavirus infection: diagnosis, treatment and prevention. Manual for physicians. M. (2006): 29 p.
  21. Paterson, E.E. Infections in obstetrics and gynecology: Trans. from English. M. MEDpress-Inform (2007): 352 p.
  22. Cancer in Ukraine in 2010-2011. Morbidity, mortality rates of cancer service // Bull. Of National Cancer Registry of Ukraine. Kyiv (2013): 124 p.
  23. “New technologies in cervical cancer prevention.” Gynecology, 1(10) (2008): 4–7.
  24. Rogovskaia, S.I. Human papillomavirus infection in women and cervical pathology: To help the practitioner. 2nd, rev. and add issue. M. GEOTAR Media (2008): 192 p.
  25. Rusakevych, P.S. Cervical disease: symptoms, diagnosis, treatment, prevention. Minsk. High School (2000): 367 p.
  26. Voloshyna, N.N. Cervical intraepithelial neoplasia (diagnosis, treatment and prevention): Guidelines. Zaporozhye (2007): 36 p.
  27. Shustyk, R., Sharova, I., Tarasiuk, T., Mysin, A. “Modern conceptions of human papillomavirus infection.”Medical Bulletin (2009): 82–85.
  28. Bosch, F.X., Lorincz, A., Munoz, N., et al. “The causal relation between human papillomavirus and cervical cancer.” J Clin Pathol, 55(2002): 244–265.
  29. Vinokurova, S., Wentzensen, N., Einenkel, J., et al. “Clonal history of papillomavirus-induced displasia in the female lower genital tract.” J Natl Cancer Inst, 24(97) (2005): 1816–1821.
  30. Bekkers, R.L., van der Avoort, I.A., Melchers, W.J., et al. “Down regulation of estrogen receptor expression is an early event in human papillomavirus infected cervical displasia.” Eur J Gynaecol Oncol, 4(26) (2005): 376–382.
  31. Jemal, A., Bray, F., Melissa, M., Ferlay, J., et al. “Global cancer statistics.” Cancer J for Clinicians, 61(2) (2011): 69–90.
  32. M onsonego, J., Magdelenat, H., Catalan, F., et al. “Estrogen and progesterone receptors in cervical human papillomavirus related lesions.” Int J Cancer, 48(4) (1991): 533–539.
  33. M unoz, N., Bosch, F.X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K.V., et al. “Epidemiologic classification of human papillomavirus types associated with cervical cancer.” N Engl J Med, 348(2003): 518–527.
  34. N air, H.B., Luthra, R., Kirma, N., et al. “Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation.” Cancer Res, 65 (2005): 11164–11173.
  35. Schlecht, N.F., Kulaga, S., Robitaille, J., et al. “Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia.” JAMA , 286 (2001): 3106–3114.
  36. R oman, A., Munger, K. “The papillomavirus E7 proteins.” Virology, Oct, 445(1-2) (2013): 138–168.
  37. Sherman, M.E. “Future directions in cervical pathology.” Future Directions in Epidemiologic and Preventive Research on Human Papillomaviruses and Cancer. In: Bosch, F.X., et al., editors. JNCI Monographs № 31. Oxford. Oxford University Press (2003): 80–88.



How to Cite

Борис, Е. Н. (2015). Modern approaches to treatment and recurrence prevention of papillomavirus-infection treatment at women of reproductive age. REPRODUCTIVE ENDOCRINOLOGY, (21), 32–39.



Tumors and pretumoral pathology